Novartis to build $23B radioligand therapy site / Beckers
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 11 days
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus / OncoDaily
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance
Friday, February 27, 2026, 11:22 pm / permalink 19912 / 6 stories in 11 days
UHS posts 11.5% operating margin in 2025 as net income jumps 30% / Beckers
Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services recorded a net income of $1.5 billion in 2025, up from $1.1 billion in 2024, according to its Feb. 25 financial report. Eight things to know: 1. The for-profit system reported an operating income of $2 …
#healthcare #publichealth #governmentpolicy #behavioralhealth #hospitaloperations #healthcarefinance
Friday, February 27, 2026, 11:25 am / permalink 19887 / 10 stories in 11 days